This site is intended for healthcare professionals only
Switching appropriate patients with type 2 diabetes to alogliptin from existing DPP-4 inhibitors: experience and outcomes from three Clinical Commissioning Groups and Local Health Boards
This supplement has been commissioned and funded by Takeda UK Ltd. It has been developed in partnership with Grey Bear Consultancy and published by Guidelines in Practice.
Content for healthcare professionals
Access to this content is restricted to UK-based doctors, nurses, and pharmacists
If you are a UK-based doctor, nurse, or pharmacist, you must sign in to your account or register (for free) if you do not already have one.